Core Viewpoint - Four Seasons Pharmaceutical (00460.HK) announced that its non-wholly owned subsidiary, Xuan Zhu Biotechnology Co., Ltd., received Fast Track designation from the FDA for the product NG-350A, intended for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) [1][2] Group 1: Company Developments - Xuan Zhu Biotechnology holds exclusive rights for the development, production, and commercialization of NG-350A in Greater China [1] - The FDA's Fast Track designation is aimed at facilitating the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need [1] Group 2: Financial Activities - On October 17, Four Seasons Pharmaceutical repurchased 15 million shares at a cost of HKD 21.758 million [2]
四环医药(00460.HK)：NG-350A获授美国FDA快速通道资格认定